相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Distribution of CGRP and CGRP receptor components in the rat brain
Karin Warfvinge et al.
CEPHALALGIA (2019)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
New strategies for the treatment and prevention of primary headache disorders
Nathaniel M. Schuster et al.
NATURE REVIEWS NEUROLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier
Sajedeh Eftekhari et al.
BRAIN RESEARCH (2015)
Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage
Cornelia Lundblad et al.
JOURNAL OF HEADACHE AND PAIN (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries
Lars Edvinsson et al.
CEPHALALGIA (2010)
Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches
Lars Edvinsson et al.
CEPHALALGIA (2010)
New drugs in migraine treatment and prophylaxis: telcagepant and topiramate
Lars Edvinsson et al.
LANCET (2010)
Current practice and future directions in the prevention and acute management of migraine
Peter J. Goadsby et al.
LANCET NEUROLOGY (2010)
CGRP and its receptors provide new insights into migraine pathophysiology
Tony W. Ho et al.
NATURE REVIEWS NEUROLOGY (2010)
Effect of two novel CGRP-binding compounds in a closed cranial window rat model
Louise Juhl et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists
Lars Edvinsson
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
分享论文
